Clinical Trials Browser

Active not recruiting × ruxolitinib × 90 days × Clear all

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04279847 2026-02-25

LIMBER

Phase 1 Active not recruiting

140 enrolled

Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT03514069 2026-02-19

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Phase 1 Active not recruiting

60 enrolled

CNS

Glioblastoma, Glioma

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

23 enrolled 18 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Phase 1 Active not recruiting

34 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT03610971 2026-01-29

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Phase 2 Active not recruiting

24 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04217356 2026-01-26

ALLO-BAT

Active not recruiting

90 enrolled

Myeloid

Bone Marrow Neoplasms, Primary Myelofibrosis

NCT06768476 2026-01-16

AML

Phase 1 Active not recruiting

12 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Clinical Trials

CINC424A2X01B Rollover Protocol

LIMBER

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

ALLO-BAT

AML